Sesterhenn IA - Search Results

1

Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.

Douglas TH, Morgan TO, McLeod DG, Moul JW, Murphy GP, Barren R 3rd, Sesterhenn IA, Mostofi FK. Douglas TH, et al. Among authors: sesterhenn ia. Cancer. 1997 Jul 1;80(1):107-14. doi: 10.1002/(sici)1097-0142(19970701)80:1<107::aid-cncr14>3.0.co;2-1. Cancer. 1997. PMID: 9210715

2

Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients.

Gao CL, Rawal SK, Sun L, Ali A, Connelly RR, Bañez LL, Sesterhenn IA, McLeod DG, Moul JW, Srivastava S. Gao CL, et al. Among authors: sesterhenn ia. Clin Cancer Res. 2003 Jul;9(7):2545-50. Clin Cancer Res. 2003. PMID: 12855629

3

Pathology of carcinoma of the prostate.

Mostofi FK, Davis CJ Jr, Sesterhenn IA. Mostofi FK, et al. Among authors: sesterhenn ia. Cancer. 1992 Jul 1;70(1 Suppl):235-53. doi: 10.1002/1097-0142(19920701)70:1+<235::aid-cncr2820701311>3.0.co;2-g. Cancer. 1992. PMID: 1376194 Review.

4

Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.

Moul JW, Sesterhenn IA, Connelly RR, Douglas T, Srivastava S, Mostofi FK, McLeod DG. Moul JW, et al. Among authors: sesterhenn ia. JAMA. 1995 Oct 25;274(16):1277-81. JAMA. 1995. PMID: 7563532

5

A pathologist's view of prostatic carcinoma.

Mostofi FK, Sesterhenn IA, Davis CJ Jr. Mostofi FK, et al. Among authors: sesterhenn ia. Cancer. 1993 Feb 1;71(3 Suppl):906-32. doi: 10.1002/1097-0142(19930201)71:3+<906::aid-cncr2820711407>3.0.co;2-i. Cancer. 1993. PMID: 7679044 Review.

6

Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.

Fernandez EB, Sesterhenn IA, McCarthy WF, Mostofi FK, Moul JW. Fernandez EB, et al. Among authors: sesterhenn ia. J Urol. 1994 Oct;152(4):1133-8. doi: 10.1016/s0022-5347(17)32522-3. J Urol. 1994. PMID: 7915335

7

Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers.

Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S. Gaddipati JP, et al. Among authors: sesterhenn ia. Cancer Res. 1994 Jun 1;54(11):2861-4. Cancer Res. 1994. PMID: 8187068

8

Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.

Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Bettencourt MC, et al. Among authors: sesterhenn ia. J Urol. 1996 Sep;156(3):1064-8. J Urol. 1996. PMID: 8709308

9

Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.

Moul JW, Bettencourt MC, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Bauer JJ. Moul JW, et al. Among authors: sesterhenn ia. Surgery. 1996 Aug;120(2):159-66; discussion 166-7. doi: 10.1016/s0039-6060(96)80283-2. Surgery. 1996. PMID: 8751578

10

Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.

Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Bauer JJ, et al. Among authors: sesterhenn ia. J Urol. 1996 Oct;156(4):1511-6. J Urol. 1996. PMID: 8808919

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

232 results

Search Page

Filters